Trials / Completed
CompletedNCT05375136
A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients
A Post Marketing Surveillance Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 135 (actual)
- Sponsor
- Eisai Korea Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Lenvatinib in lenvatinib/pembrolizumab combination therapy in the post marketing setting: (1) Serious adverse events and serious adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in the approved product package insert of lenvatinib in lenvatinib/pembrolizumab combination therapy (3) Known adverse drug reactions (4) Non-serious adverse drug reactions (5) Other safety and efficacy related information.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non-interventional | No intervention will be administered. |
Timeline
- Start date
- 2021-06-25
- Primary completion
- 2023-11-07
- Completion
- 2023-11-07
- First posted
- 2022-05-16
- Last updated
- 2024-03-25
Locations
19 sites across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05375136. Inclusion in this directory is not an endorsement.